Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02677181
- Locations
- 🇨🇳
Liping Dou, Beijing, Beijing, China
Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02660684
Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT02630563
Efficacy and Safety of HE10 for Dry Eye Syndrome
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Huons Co., Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT02492412
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 876
- Registration Number
- NCT02487069
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02478424
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02462252
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 158
- Registration Number
- NCT02461719
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 29
- Registration Number
- NCT02435901
- Locations
- 🇺🇸
Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Robert Lowsky
- Target Recruit Count
- 18
- Registration Number
- NCT02424968
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.